47 results on '"Barraco, Daniela"'
Search Results
2. S173: RETROSPECTIVE STUDY OF LENALIDOMIDE DISCONTINUATION IN PATIENTS WITH MYELODYSPLASTIC SYNDROME HARBORING DEL(5Q). A HARMONY ALLIANCE STUDY
3. Targeted deep sequencing in polycythemia vera and essential thrombocythemia
4. Efficacy and Safety of Luspatercept in Adult Patients with Transfusion-Dependent Anemia Due to Very Low, Low and Intermediate Risk Myelodysplastic Syndromes (MDS) with Ring Sideroblasts, Who Had an Unsatisfactory Response to or Are Ineligible for Erythropoietin-Based Therapy: A Retrospective Multicenter Study By Fondazione Italiana Sindromi Mielodisplastiche (FiSiM ETS)
5. Chronic Myeloid Leukemia Diagnosed during Pregnancy: How to Manage? Description of 86 Cases from ELN International Registry
6. Gender effect on phenotype and genotype in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis: results from the MYSEC project
7. Momelotinib therapy for myelofibrosis: a 7-year follow-up
8. Gender and survival in essential thrombocythemia: A two‐center study of 1,494 patients
9. DNMT3A mutations are associated with inferior overall and leukemia‐free survival in chronic myelomonocytic leukemia
10. Calreticulin variant stratified driver mutational status and prognosis in essential thrombocythemia
11. Next generation sequencing of myeloid neoplasms with eosinophilia harboring the FIP1L1-PDGFRA mutation
12. Long-term efficacy and safety of nilotinib therapy after imatinib failure in eosinophilic myeloproliferative neoplasm and ETV6-ABL rearrangement
13. Clinical factors predictive of myelofibrotic evolution in patients with polycythemia vera
14. Impact of Bone Marrow Fibrosis Grade in Post-Polycythemia Vera and Post-Essential Thrombocythemia Myelofibrosis. a Study of the Mysec Group
15. Standard care and investigational drugs in the treatment of myelofibrosis
16. Second primary malignancies in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 2233 patients
17. Solid Tumors in Post-Polycythemia Vera and Post-Essential Thrombocythemia Myelofibrosis: A Study on 2220 Patients
18. Value of cytogenetic abnormalities in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study of the MYSEC project
19. Monocytosis in polycythemia vera: Clinical and molecular correlates
20. Targeted next generation sequencing and identification of risk factors in World Health Organization defined atypical chronic myeloid leukemia
21. The prognostic relevance of serum lactate dehydrogenase and mild bone marrow reticulin fibrosis in essential thrombocythemia
22. DNMT3A mutations are associated with inferior overall and leukemia-free survival in chronic myelomonocytic leukemia
23. Gene Expression Profiling Identifies Distinct Signatures for Dysplastic and Proliferative Chronic Myelomonocytic Leukemia
24. Risk Factors for Arterial Versus Venous Thrombosis in Polycythemia Vera: Single Center Experience in 587 Patients
25. Spectrum of Concomitant and Subsequently Diagnosed Second Malignancies in Patients with Chronic Myelomonocytic Leukemia
26. Prognostic Impact of Bone Marrow Fibrosis in Polycythemia Vera: Validation of the IWG-MRT Study and Additional Observations
27. U2AF1 Mutation Variants and Their Phenotypic and Prognostic Relevance in Primary Myelofibrosis
28. Identification of Serum Lactate Dehydrogenase (LDH) As an Independent Prognostic Biomarker in Polycythemia Vera
29. Abnormal Karyotype and Prognosis in Polycythemia Vera: A Single Center Experience in 239 Informative Cases
30. The Prognostic Relevance of Serum Lactate Dehydrogenase and Mild Reticulin Fibrosis in Essential Thrombocythemia
31. Monocytosis Is a Powerful and Independent Predictor of Shortened Overall and Leukemia-Free Survival in Primary Myelofibrosis
32. Prefibrotic Versus Overtly Fibrotic Primary Myelofibrosis: Clinical, Cytogenetic, Molecular and Prognostic Comparisons
33. Marked Elevation of Serum Lactate Dehydrogenase (LDH) in Primary Myelofibrosis: Clinical and Prognostic Correlates
34. Momelotinib Therapy in Myelofibrosis: 6-Years Follow-up Data on Safety, Efficacy and the Impact of Mutations on Overall and Relapse-Free Survival
35. Monocytosis in Polycythemia Vera: Clinical and Molecular Correlates
36. Next generation sequencing of myeloid neoplasms with eosinophilia harboring theFIP1L1-PDGFRAmutation
37. Impact of bone marrow fibrosis grade in post‐polycythemia vera and post‐essential thrombocythemia myelofibrosis: A study of the MYSEC group.
38. Molecular Correlates of Anemia in Primary Myelofibrosis
39. A 27-Gene NGS Panel in Primary Myelofibrosis Identifies ASXL1, CBL, RUNX1 and SRSF2 Mutations As Being Unfavorable and Absence of Any Non-Driver Mutation As Being Favorable to Survival
40. Targeted Next-Generation Sequencing in Polycythemia Vera and Essential Thrombocythemia
41. The Anatomy of Recurrent Thrombosis and Its Risk Factors in Myeloproliferative Neoplasms
42. Phenotypic and Prognostic Relevance of the Who Diagnostic Distinction between Polycythemia Vera and JAK2 -Mutated Essential Thrombocythemia: Combined Analysis of 785 Informative Cases
43. Clinical factors predictive of myelofibrotic evolution in patients with polycythemia vera
44. Clinical Factors Predictive Of Myelofibrotic Evolutions In Patients With Essential Thrombocythemia and Polycythemia Vera
45. U2AF1Mutation Variants and Their Phenotypic and Prognostic Relevance in Primary Myelofibrosis
46. A 27-Gene NGS Panel in Primary Myelofibrosis Identifies ASXL1, CBL, RUNX1and SRSF2Mutations As Being Unfavorable and Absence of Any Non-Driver Mutation As Being Favorable to Survival
47. Real-world efficacy and safety of luspatercept and predictive factors of response in patients with lower risk myelodysplastic syndromes with ring sideroblasts.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.